CN111443201A - Aspirin drug resistance detection kit - Google Patents
Aspirin drug resistance detection kit Download PDFInfo
- Publication number
- CN111443201A CN111443201A CN202010114209.6A CN202010114209A CN111443201A CN 111443201 A CN111443201 A CN 111443201A CN 202010114209 A CN202010114209 A CN 202010114209A CN 111443201 A CN111443201 A CN 111443201A
- Authority
- CN
- China
- Prior art keywords
- thromboxane
- reagent
- dehydro
- aspirin
- creatinine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 39
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 28
- 206010059866 Drug resistance Diseases 0.000 title claims abstract description 14
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims abstract description 50
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 44
- KJYIVXDPWBUJBQ-UHHGALCXSA-N 11-dehydro-thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(=O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O KJYIVXDPWBUJBQ-UHHGALCXSA-N 0.000 claims abstract description 34
- 229940109239 creatinine Drugs 0.000 claims abstract description 25
- 102000004190 Enzymes Human genes 0.000 claims abstract description 13
- 108090000790 Enzymes Proteins 0.000 claims abstract description 13
- 208000025870 aspirin resistance Diseases 0.000 claims abstract description 10
- 238000003018 immunoassay Methods 0.000 claims abstract description 10
- 230000002485 urinary effect Effects 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims description 9
- 210000002700 urine Anatomy 0.000 claims description 9
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims description 7
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims description 7
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims description 7
- 238000003908 quality control method Methods 0.000 claims description 6
- KJYIVXDPWBUJBQ-UHFFFAOYSA-N 11-Dehydro-Thromboxane B2 Natural products CCCCCC(O)C=CC1OC(=O)CC(O)C1CC=CCCCC(O)=O KJYIVXDPWBUJBQ-UHFFFAOYSA-N 0.000 claims description 4
- 102000016938 Catalase Human genes 0.000 claims description 4
- 108010053835 Catalase Proteins 0.000 claims description 4
- 108010060059 Sarcosine Oxidase Proteins 0.000 claims description 4
- 102000008118 Sarcosine oxidase Human genes 0.000 claims description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N anhydrous creatine Natural products NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 4
- 108010066906 Creatininase Proteins 0.000 claims description 3
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 claims description 3
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 claims description 3
- 229960003624 creatine Drugs 0.000 claims description 3
- 239000006046 creatine Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 108090000604 Hydrolases Proteins 0.000 claims description 2
- 102000004157 Hydrolases Human genes 0.000 claims description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 2
- 238000003149 assay kit Methods 0.000 claims description 2
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 206010000891 acute myocardial infarction Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000010219 correlation analysis Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108010077078 Creatinase Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 238000013176 antiplatelet therapy Methods 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 229940085430 aspirin 300 mg Drugs 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides an aspirin drug resistance detection kit, which is used for detecting 11-dehydro-thromboxane B in human urine2The ratio of the aspirin and the creatinine is used for judging the aspirin resistance degree of a patient, and the method is characterized in that a homogeneous enzyme immunoassay method is adopted for measuring 11-dehydro-thromboxane B in human urine2The content of the (D) has the characteristics of no wound, high automation degree, rapid detection, low cost and the like; the kit simultaneously comprises a urinary creatinine detection reagent, the two detections can be simultaneously carried out on a full-automatic biochemical analyzer, and the detection result can be automatically calculated.
Description
Technical Field
The invention belongs to the field of in-vitro diagnosis, and particularly relates to an aspirin resistance detection kit which is used for determining aspirin resistance of a human body.
Background
Cardiovascular and cerebrovascular diseases caused by thrombus become one of the main diseases endangering the health of people, and have the characteristics of high morbidity, high disability rate, high death rate and high recurrence rate. At present, evidence of evidence-based medicine at home and abroad proves that the continuous use of antithrombotic drugs and the effective control of risk factors are very critical to the improvement of the prognosis of patients. Aspirin is a salicylic acid non-steroidal anti-inflammatory drug, and can achieve an antithrombotic effect by intervening platelet aggregation. Recent guidelines set forth by the american heart association and the american stroke association emphasize that aspirin is an important first-line treatment and second-line prophylactic for patients with acute myocardial infarction. China 'diagnosis and treatment guidelines for acute myocardial infarction' also clearly points out that: as an antiplatelet therapy, all patients with acute myocardial infarction without contraindications should take water-soluble aspirin or chewable enteric aspirin 300mg immediately, and then maintain the aspirin for a long time at 75-100 mg/d; and after the patient is discharged from hospital, 75-100 mg/d of aspirin should be taken for a long time.
However, the therapeutic effect of aspirin is very limited for some patients. According to statistics, about 15-25% of patients with arterial thrombosis still have platelet activation and aggregation to form vascular embolism when taking aspirin for treatment, and the condition is called high aspirin platelet reaction and also called aspirin resistance. Therefore, there is a need for a reliable way for clinicians to analyze an individual's specific response to aspirin to assist the physician in determining treatment and adjusting the type and dosage of the individual accordingly. Studies have shown that 11-dehydro-thromboxane B is present in urine2(11-dehydro-thromboxane B2,11-dhTXB2) The ratio of the content to the creatinine content can accurately reflect the treatment effect of patients after taking aspirin, can predict the risk of cardiovascular and cerebrovascular accidents of the patients, and has extremely high clinical value.
11-dhTXB2Is one of metabolites of arachidonic acid in human urine, belongs to a small molecular compound, and has concentration related to water intake of patients, usually 300-5000 pg/ml. Due to 11-dhTXB in urine2The content is extremely low, and the urine components are complex and the number of interferents is large, so that the quantitative measurement of the urine is very difficult clinically. At present, the detection methods which can be practically applied are a chromatography method and an enzyme-linked immunosorbent assay, and the two detection methods have the disadvantages of complex operation process, long detection period, expensive equipment and manual operation, so that the application of the item is limited.
In summary, in the aspect of accurate aspirin administration, a detection method and a detection reagent which can be developed on a large scale and are low in cost are urgently needed clinically.
Disclosure of Invention
The invention provides an aspirin drug resistance detection kit, which is used for detecting 11-dehydro-thromboxane B in human urine2The ratio of the aspirin and the creatinine is used for judging the aspirin drug resistance degree of a patient, and the method is characterized in that a homogeneous enzyme immunoassay method is adopted for measuring 11-deaths in human urineHydro-thromboxane B2The content of the (D) has the characteristics of no wound, high automation degree, rapid detection, low cost and the like; the kit simultaneously comprises a urinary creatinine detection reagent, the two detections can be simultaneously carried out on a full-automatic biochemical analyzer, and the detection result can be automatically calculated.
The content of the invention comprises:
[1]an aspirin drug resistance detection kit, which is used for detecting 11-dehydro-thromboxane B in human urine2The ratio of the aspirin to the creatinine is used for judging the drug resistance of the patient to the aspirin; the kit consists of 11-dehydro-thromboxane B2The determination part, the creatinine determination part, the standard substance and the quality control substance are composed of 11-dehydro-thromboxane B in a kit2A homogeneous enzyme immunoassay method is used in the determination reagent;
[2][1]the homogeneous enzyme immunoassay method for the determination of 11-dehydro-thromboxane B as described in (1)2The reagent (2) consists of two parts (i.e. a first reagent R1 and a second reagent R2), characterized in that one of the reagents contains a labeled 11-dehydro-thromboxane B2The glucose-6-phosphate dehydrogenase of (1), correspondingly, another reagent contains 11-dehydro-thromboxane B2Antibody and substrate for glucose-6-phosphate dehydrogenase: oxidized Nicotinamide Adenine Dinucleotide (NAD)+) And glucose-6-phosphate (or a salt thereof);
[3] the urinary creatinine assay kit described in [1] consists of two parts (i.e. a third reagent R3 and a fourth reagent R4), and the components of the kit are consistent with those of a commercially available enzyme method creatinine determination reagent, namely R3 contains creatine hydrolase, sarcosine oxidase and catalase, and R4 contains creatinine hydrolase;
[4][1]the standard substance and the quality control substance of the aspirin drug resistance detection kit comprise creatinine and 11-dehydro-thromboxane B with certain concentration2The solution was mixed.
In particular, the use of the kit of the invention comprises 11-dehydro-thromboxane B2The determination and the creatinine determination are carried out on a full-automatic biochemical analyzer by using a double-channel four-reagent mode.
Wherein, 11-dehydro-thromboxane B2The detection is based on a homogeneous enzyme immunoassay, whichThe measurement principle is as follows: free 11-dehydro-thromboxane B in the sample2And 11-dehydro-thromboxane B labeled on glucose-6-phosphate dehydrogenase2Competitively bind 11-dehydro-thromboxane B2An antibody; when the antibody binds to glucose-6-phosphate dehydrogenase, the enzyme activity of glucose-6-phosphate dehydrogenase is greatly reduced, so that 11-dehydro-thromboxane B in the sample2The content is in direct proportion to the activity of the glucose-6-phosphate dehydrogenase in the detection system; by comparing with standard product, 11-dehydro-thromboxane B in the sample can be calculated2The content of (a).
The creatinine detection adopts an enzyme method, and the specific determination principle is as follows: creatine and sarcosine in the urine sample are eliminated by creatinase, sarcosine oxidase and catalase, and then sodium azide is used for inhibiting the activity of catalase in a system; then, creatinine reacts with creatininase, creatinase and sarcosine oxidase in sequence to generate hydrogen peroxide, the hydrogen peroxide is developed by utilizing Trinder's reaction, and the content of the creatinine in the sample can be calculated through comparison with a standard product.
Finally, by 11-dehydro-thromboxane B2And creatinine ratio to determine the patient's resistance to aspirin.
Drawings
FIG. 1 is a diagram of the correlation analysis of the kit.
Detailed Description
The following are specific examples of the present invention and further describe the technical solutions of the present invention, but the present invention is not limited to these examples.
The reagents used in the examples are shown in table one.
Table one: sources of reagents in the examples
Example 1: preparation of aspirin drug resistance detection kit
The aspirin drug resistance detection kit is prepared by the following method:
[1]preparing 11-dehydro-thromboxane B according to Table II2The reagent first, R1 in an aspirin resistance detection kit, was measured and its pH adjusted to 8.50.
Table two: 11-dehydro-thromboxane B2Assay reagent first reagent formulation
[2]Preparing 11-dehydro-thromboxane B according to the third formula2The reagent second, R2 in an aspirin resistance detection kit, was measured and its pH adjusted to 8.50.
Table three: 11-dehydro-thromboxane B2Assay reagents second reagent formulations
[3] A first reagent of the urine creatinine assay reagent, namely R3 in the aspirin resistance detection kit, is prepared according to the fourth table.
Table four: first reagent formula of urine creatinine determination reagent
[4] And preparing a second reagent of the urine creatinine determination reagent, namely R4 in the aspirin resistance detection kit according to the fifth table.
Table five: second reagent formula of urine creatinine determination reagent
The R1, R2, R3 and R4 prepared according to the scheme, a calibrator and a quality control product are combined to form the aspirin drug resistance detection kit.
Example 2: detection of aspirin drug resistance detection reagent and detection result
The performance of the aspirin resistance kit prepared in example 1 was used for detection according to the following procedure.
(1) Setting reaction parameters of a full-automatic biochemical analyzer: biochemical analyzer parameters of 11-dehydro-thromboxane B2 and creatinine were set according to table six and table seven, respectively.
TABLE VI.11-dehydro-thromboxane B2Biochemical instrument for measuring parameters
TABLE seven. measurement parameters of urocreatinine biochemical instrument
(2) Obtaining a standard curve
And (4) measuring the standard substance on a biochemical analyzer according to the parameters to obtain a standard curve.
(3) Sample detection
The standard curve obtained by the homogeneous enzyme immunoassay reagent of the invention is used for repeatedly measuring the high and low quality control samples for 10 times, and the detection data and the data analysis are shown in the table eight.
TABLE VIII reaction parameters of full-automatic biochemical analyzer
And (3) detection results: the homogeneous enzyme immunoassay reagent has high accuracy and high precision, and CV is lower than 5%.
(4) Correlation analysis
The correlation analysis is carried out on 50 cases of clinical samples by respectively using a high performance liquid chromatography and the homogeneous phase enzyme immunoassay reagent of the invention, the measured data are shown in figure 1, and the obtained linear equation is as follows: y = 0.9838x +14.324 and the correlation coefficient R2 =0.9885, indicating that the detection reagent of the present invention determines 11-dehydrothromboxane B2The accuracy of clinical specimens is high.
It should be noted that the above-mentioned embodiments illustrate rather than limit the invention, and the scope of the invention is defined by the appended claims. Several modifications can be made without departing from the scope of the invention, and these modifications should also be construed as within the scope of the invention.
Claims (4)
1. In an aspirin drug resistance detection kit, the kit determines the drug resistance of a patient to aspirin by determining the ratio of 11-dehydro-thromboxane B2 to creatinine in human urine, and is characterized in that a homogeneous enzyme immunoassay method is used in an 11-dehydro-thromboxane B2 determination reagent of the kit, and the kit consists of a 11-dehydro-thromboxane B2 determination part, a creatinine determination part, a standard substance and a quality control substance.
2. The homogeneous enzyme immunoassay method of claim 1 for the determination of 11-dehydro-thromboxane B2The reagent (2) consists of two parts (i.e. a first reagent R1 and a second reagent R2), characterized in that one of the reagents contains a labeled 11-dehydro-thromboxane B2The glucose-6-phosphate dehydrogenase of (1), correspondingly, another reagent contains 11-dehydro-thromboxane B2Antibody and substrate for glucose-6-phosphate dehydrogenase: oxidized Nicotinamide Adenine Dinucleotide (NAD)+) And glucose-6-phosphate (or a salt thereof).
3. The urinary creatinine assay kit according to claim 1, which comprises two reagents (i.e., the third reagent R3 and the fourth reagent R4) and has a composition similar to that of a commercially available reagent for measuring creatinine by an enzymatic method, i.e., R3 contains creatine hydrolase, sarcosine oxidase and catalase, and R4 contains creatinine hydrolase.
4. The aspirin resistance test kit in claim 1, wherein the standard substance and quality control substance are creatinine and 11-dehydro-thromboxane B in certain concentration2The solution was mixed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010114209.6A CN111443201A (en) | 2020-02-25 | 2020-02-25 | Aspirin drug resistance detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010114209.6A CN111443201A (en) | 2020-02-25 | 2020-02-25 | Aspirin drug resistance detection kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111443201A true CN111443201A (en) | 2020-07-24 |
Family
ID=71627149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010114209.6A Pending CN111443201A (en) | 2020-02-25 | 2020-02-25 | Aspirin drug resistance detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111443201A (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6413459A (en) * | 1987-07-08 | 1989-01-18 | Ono Pharmaceutical Co | Enzyme labeled thronboxane b2 and method for measuring 11-dehydro-thromboxane b2 |
| EP0336647A2 (en) * | 1988-03-31 | 1989-10-11 | Sankyo Company Limited | Determination of arachidonic acid derivatives and kits therefore |
| US20030124615A1 (en) * | 1999-10-25 | 2003-07-03 | Esoterix, Inc. Coagulation | Thromoboxane B2 metabolite and methods for regulating aspirin-related platelet action |
| US20040115735A1 (en) * | 2002-03-24 | 2004-06-17 | Salim Yusuf | Method for predicting cardiovascular events |
| US20070202556A1 (en) * | 2005-12-09 | 2007-08-30 | Corgenix Medical Corporation | Methods and kits for detection of thromboxane a2 metabolites |
| CN102323414A (en) * | 2011-06-07 | 2012-01-18 | 西安金域医学检验所有限公司 | Phenobarbital homogeneous-phase enzyme immunoassay reagent kit and preparation method thereof |
| CN106124779A (en) * | 2016-06-15 | 2016-11-16 | 四川迈克生物科技股份有限公司 | A kind of test kit for measuring creatinine and method |
| CN106198509A (en) * | 2016-06-15 | 2016-12-07 | 四川迈克生物科技股份有限公司 | For measuring test kit and the method for creatinine |
| CN108627654A (en) * | 2018-06-25 | 2018-10-09 | 武汉瀚海新酶生物科技有限公司 | Composition for eliminating Calcium Dobesilate drug to the detection interference of creatinine enzyme process |
| CN109613226A (en) * | 2019-01-24 | 2019-04-12 | 浙江夸克生物科技有限公司 | A kind of creatinine assay kit and its application |
| CN111733208A (en) * | 2020-08-15 | 2020-10-02 | 中山标佳生物科技有限公司 | A kind of creatinine test kit capable of eliminating calcium dobesilate, sulfoethylamine and preparation method thereof |
-
2020
- 2020-02-25 CN CN202010114209.6A patent/CN111443201A/en active Pending
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6413459A (en) * | 1987-07-08 | 1989-01-18 | Ono Pharmaceutical Co | Enzyme labeled thronboxane b2 and method for measuring 11-dehydro-thromboxane b2 |
| EP0336647A2 (en) * | 1988-03-31 | 1989-10-11 | Sankyo Company Limited | Determination of arachidonic acid derivatives and kits therefore |
| US20030124615A1 (en) * | 1999-10-25 | 2003-07-03 | Esoterix, Inc. Coagulation | Thromoboxane B2 metabolite and methods for regulating aspirin-related platelet action |
| US20040115735A1 (en) * | 2002-03-24 | 2004-06-17 | Salim Yusuf | Method for predicting cardiovascular events |
| US20070202556A1 (en) * | 2005-12-09 | 2007-08-30 | Corgenix Medical Corporation | Methods and kits for detection of thromboxane a2 metabolites |
| CN102323414A (en) * | 2011-06-07 | 2012-01-18 | 西安金域医学检验所有限公司 | Phenobarbital homogeneous-phase enzyme immunoassay reagent kit and preparation method thereof |
| CN106124779A (en) * | 2016-06-15 | 2016-11-16 | 四川迈克生物科技股份有限公司 | A kind of test kit for measuring creatinine and method |
| CN106198509A (en) * | 2016-06-15 | 2016-12-07 | 四川迈克生物科技股份有限公司 | For measuring test kit and the method for creatinine |
| CN108627654A (en) * | 2018-06-25 | 2018-10-09 | 武汉瀚海新酶生物科技有限公司 | Composition for eliminating Calcium Dobesilate drug to the detection interference of creatinine enzyme process |
| CN109613226A (en) * | 2019-01-24 | 2019-04-12 | 浙江夸克生物科技有限公司 | A kind of creatinine assay kit and its application |
| CN111733208A (en) * | 2020-08-15 | 2020-10-02 | 中山标佳生物科技有限公司 | A kind of creatinine test kit capable of eliminating calcium dobesilate, sulfoethylamine and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barsotti | Measurement of ammonia in blood | |
| Foster et al. | A single-reagent manual method for directly determining urea nitrogen in serum | |
| Bode et al. | Spontaneous decay of oxidized ascorbic acid (dehydro-L-ascorbic acid) evaluated by high-pressure liquid chromatography | |
| Lyman | Blood urea nitrogen and creatinine | |
| Witte et al. | Evaluation of an enzymatic procedure for determination of serum cholesterol with the Abbott ABA-100 | |
| US6762035B1 (en) | Method and test strips for the measurement of fat loss during weight loss programs | |
| US6790668B1 (en) | Monitoring patient compliance and bioavailability of drugs by deproteinizing body fluids | |
| WO2022095576A1 (en) | NOVEL N-ACETYL-β-D GLUCOSAMINIDASE DETECTION AGENT | |
| CN102798726B (en) | Cobalamin chemiluminescence immunoassay immue quantitative detection reagent box and preparation method thereof | |
| CN112029817B (en) | A creatinine detection kit and its use method | |
| CN111289501A (en) | Kit for detecting NO based on indirect colorimetric method and preparation and use methods thereof | |
| JPS6091998A (en) | Novel enzymatic measurement of d-3-hydroxybutyric acid and acetoacetic acid in humors, urine and measurement reagent for it | |
| CN113655006B (en) | Urinary system knot Dan Chengdan risk factor detection and test system | |
| CN111443201A (en) | Aspirin drug resistance detection kit | |
| CN108359710A (en) | The enzyme colour developing quantitative determination reagent kit and assay method of glucosephosphate isomerase | |
| US4095948A (en) | Determination of uric acid | |
| CN108956971A (en) | A kind of valproic acid immunologic function test reagent and its preparation and detection method | |
| JP4217815B2 (en) | Method for quantifying glucose by glucose dehydrogenase and reagent for quantifying glucose | |
| JP2003502055A (en) | A rapid and sensitive assay for homocysteine | |
| CN108593905A (en) | A digoxin immunoassay reagent and its preparation and detection method | |
| Chen et al. | Fluorescence polarization immunoassay and HPLC assays compared for measuring monoethylglycinexylidide in liver-transplant patients | |
| Kiang et al. | Semi-solid surface fluorometric analysis of glucose | |
| CN1924580B (en) | Chemiluminescent Assay Kit for Quantitative Detection of Triiodothyronine | |
| CN113533577A (en) | Method for simultaneously determining blood concentration of vancomycin and aminophylline and application | |
| Okuda et al. | Rapid and successive microdeterminations of oxygen, d-glucose, and its anomers in blood with β-d-glucose oxidase and oxygen electrode |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200724 |